Introducing PwC's Health Policy and Intelligence Institute (HPII)

NEW YORK, NY USA USA -- HEALTHCARE UPDATE NEWS SERVICE™ -- DECEMBER 19, 2024: We were honored to be part of the 25th Annual Pharmaceutical and Medical Device Ethics and Compliance Conference in October, where we discussed both the benefits of Integrated Risk Management, and importance of effective change management during a compliance program transformation. In case you missed the event or our sessions, you can read our key takeaways.

PwC would also like to introduce you to our Health Policy and Intelligence Institute (HPII). The institute distills regulatory developments and provides meaningful perspectives on the impact to the healthcare marketplace to help you manage uncertainty and make better decisions. Below are a few of the latest articles that may be of interest:

• President-elect Donald Trump's healthcare agenda: deregulation, flexibility and choice, accessibility and national security offers a deep dive into the anticipated policy shifts and regulatory changes under President-elect Trump's administration, which are poised to significantly impact the health industry.
  
  
• A second Trump administration could mark a significant shift in the political landscape with considerable implications for the health industry. Kelly Griffin, Director, HPII, explores potential health policy changes, anticipated actions within the first 100 days, and what to expect for the remainder of 2025 in PwC's Policy on Demand.
  
  
• The DOJ's updated Evaluation of Corporate Compliance Programs (ECCP) focuses on emerging technologies, whistleblower protection, M&A integration and more. Learn how health industry compliance leaders may respond in our article, DOJ updates expectations for compliance programs.
  
  
• Monthly regulatory alerts on recent regulatory changes impacting health industries. Subscribe to receive our alerts each month.